Alkermes raises offer for Avadel after Lundbeck bid

Core Viewpoint - Alkermes has increased its acquisition offer for Avadel Pharmaceuticals, surpassing a competing bid from Lundbeck, with a total valuation of up to $2.37 billion [1] Company Summary - Alkermes is actively pursuing Avadel Pharmaceuticals, indicating a strategic move to enhance its portfolio in the sleep disorder market [1] - Avadel Pharmaceuticals is being valued at up to $2.37 billion, reflecting its potential in the pharmaceutical industry [1] Competitive Landscape - The acquisition bid from Alkermes is positioned against a rival offer from Lundbeck, highlighting competitive dynamics in the pharmaceutical sector [1]